Skip to content
thispeptide

Ozempic Diarrhea: How Common It Is, How Long It Lasts and When to Call

Diarrhea affected about 9% of people on Ozempic in the diabetes trials and 30% at the higher Wegovy dose. Most cases came while the dose was being raised.

Article type
Safety
Sources
5
Reading
6 min
By Molly WardPublished

Yes, Ozempic can cause diarrhea. It is one of the five most common side effects on the label. Ozempic is a brand of semaglutide, a weekly GLP-1 injection. The drug itself is covered in the semaglutide guide.

Here is how often it happened in the trials, when it tends to start and settle, and what an expert panel suggested. You will also find the point where the label says to call your provider.

How many people get diarrhea on Ozempic?

The Ozempic label reports placebo-controlled trials in adults with type 2 diabetes [1]. Diarrhea affected 1.9% on placebo, 8.5% on 0.5 mg and 8.8% on 1 mg.

Nausea was more common than diarrhea at both doses. Vomiting, abdominal pain and constipation made up the rest of the label’s top five.

Wegovy uses the same drug at higher doses for weight loss. In its adult weight trials at 2.4 mg, diarrhea affected 30% on Wegovy and 16% on placebo [2].

Diarrhea in the semaglutide label trials
LabelTrialsOn semaglutideOn placebo
Ozempic 0.5 mgType 2 diabetes, placebo-controlled8.5%1.9%
Ozempic 1 mgType 2 diabetes, placebo-controlled8.8%1.9%
Wegovy 2.4 mgAdults, weight reduction30%16%
Wegovy 2.4 mgAges 12 and older, weight reduction22%19%
Diarrhea in the semaglutide label trials

Across the whole drug class, a 2026 meta-analysis pooled 101 randomized trials [4]. Diarrhea came out roughly twice as likely as on placebo (risk ratio 1.97), with an overall incidence of 13%.

In head-to-head comparisons, that analysis found tirzepatide carried the highest risk ratio for diarrhea. The tirzepatide side is covered in tirzepatide diarrhea.

When does it start, and does it stop?

The Ozempic label says most reports of nausea, vomiting and diarrhea came during dose escalation [1]. That is the stretch when the weekly dose is being stepped up.

A 2022 analysis pooled the STEP 1 to 3 weight trials, with 2,117 people on semaglutide 2.4 mg [3]. It described the stomach side effects as mostly transient and most frequent during or shortly after escalation.

An expert consensus from 2022 puts the timing more precisely [5]. It says diarrhea starts in the first four weeks of GLP-1 treatment, after which new cases drop off.

The same panel says symptoms have been reported to last about three days in people with obesity. That figure comes from the panel’s review, not from the Ozempic label.

How serious does it usually get?

In the pooled STEP analysis, 99.5% of stomach side effects on semaglutide were non-serious [3]. Of them, 98.1% were mild to moderate.

Few people quit over them. In the Ozempic trials, 3.1% on 0.5 mg and 3.8% on 1 mg stopped because of stomach side effects, against 0.4% on placebo [1].

In the Wegovy weight trials, diarrhea alone led 0.7% of people to stop, against 0.1% on placebo [2].

What the expert panel suggests

The 2022 consensus paper came from a panel of endocrinologists, kidney specialists, cardiologists, internists, primary care doctors and diabetes nurse educators [5]. Its diarrhea advice starts with fluids.

The panel’s list for people with diarrhea includes:

  • Generous hydration, such as water with lemon and a teaspoon of bicarbonate.
  • Avoiding sports drinks meant for exercise.
  • Avoiding dairy, coffee, alcohol, soft drinks and very hot or very cold foods.
  • Avoiding sweeteners that end in “ol,” such as sorbitol and xylitol, including in gum and candy.
  • Cutting back on high-fiber foods for a while, then adding fiber back as symptoms settle.

If diarrhea persists despite those steps, the panel says a clinician could consider a probiotic or an antidiarrheal such as loperamide. That is a question for your prescriber.

The panel also flags one combination. GLP-1 drugs may worsen diarrhea in people taking metformin, especially with omeprazole. It suggests a lower metformin dose may help in that case.

When diarrhea is more than a nuisance

The label’s concern is fluid loss. It reports acute kidney injury in people on semaglutide, sometimes needing dialysis [1].

Most of those cases followed stomach side effects that led to dehydration, such as nausea, vomiting or diarrhea. The kidney side is covered in can Ozempic cause kidney problems.

The Medication Guide is direct about it. It says it is important “to drink fluids to help reduce your chance of dehydration.”

It also says to tell your provider “right away if you have nausea, vomiting, or diarrhea that does not go away.” More on fluids is in does Ozempic cause dehydration.

Nausea usually arrives alongside it, and is covered in Ozempic nausea. The full list is in semaglutide side effects.

Frequently asked questions

Does Ozempic cause diarrhea?
Yes. In the Ozempic placebo-controlled diabetes trials, diarrhea affected 8.5% of people on 0.5 mg and 8.8% on 1 mg, against 1.9% on placebo. It is one of the five most common side effects on the label.
How long does Ozempic diarrhea last?
The label says most reports came during dose escalation. A 2022 expert consensus says GLP-1 diarrhea usually starts in the first four weeks and that symptoms have been reported to last about three days in people with obesity.
Is diarrhea more common on Wegovy than Ozempic?
At the Wegovy dose of 2.4 mg, diarrhea affected 30% of adults in the weight trials, against 16% on placebo. The Ozempic figures come from different trials in people with type 2 diabetes, so the two are not a direct comparison.
When should you call a provider about diarrhea on Ozempic?
The Ozempic Medication Guide says to tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away. The label links fluid loss from these side effects to acute kidney injury.
Does diarrhea on semaglutide mean you will lose more weight?
No. A pooled analysis of the STEP 1 to 3 trials found weight loss was similar in people with and without stomach side effects, and less than 1 percentage point of the extra loss was explained by them.

Sources

5 cited
  1. 1DailyMed, U.S. National Library of Medicine (2026). OZEMPIC (semaglutide) injection, for subcutaneous use: prescribing information (DailyMed version effective 06/2026) DailyMed. Source
  2. 2DailyMed, U.S. National Library of Medicine (2026). WEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablets: prescribing information (revised 06/2026) DailyMed. Source
  3. 3Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, Mosenzon O, Rubino DM, Thomsen M, Wadden TA, Pedersen SD (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Diabetes Obes Metab. PMID 34514682
  4. 4Joy B, Ramsamooj A, Ibrahim S, Wen J, Hsu N, Frezza E (2026). Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials Endocrine. PMID 41489846
  5. 5Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, Castro A, Cebrián-Cuenca A, de Torres-Sánchez A, García-de-Lucas MD, Núñez J, Obaya JC, Soler MJ, Górriz JL, Rubio-Herrera MÁ (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus J Clin Med. PMID 36614945

More on weight